单基因脑小血管病的神经系统及神经系统外症状：对诊断的提示

doi:10.3969/j.issn.1673-5765.2025.06.015

摘要/Abstract

摘要： 脑小血管病（cerebral small vessel disease，CSVD）是一组病因复杂的神经系统疾病，主要表现为缺血或出血性卒中，以及认知功能障碍、精神情感异常和步态障碍等，神经影像学特征包括近期皮质下梗死、血管周围间隙扩大、脑微出血、颅内出血、脑萎缩、血管源性腔隙灶和脑白质病变。单基因CSVD是其中一类罕见的亚型，占全部病因的1%～5%，目前已报道的CSVD致病基因达数十个。除CSVD共同的临床和影像学表现外，单基因CSVD常有特异性的表现，尤其是神经系统外症状，对诊断具有较强的提示作用。鉴于CSVD相关基因的检测分析耗时且具有挑战性，全面认识单基因CSVD的神经系统症状和神经系统外症状将有助于指导其早期诊疗。本文旨在总结单基因CSVD的神经系统症状、神经系统外症状、神经影像学特征及其对临床诊断的价值。

文章导读： 本文综述了单基因脑小血管病的神经系统和神经系统外症状，以及特异性神经影像学表现，有助于临床医师全面认识和识别单基因脑小血管病，便于早期诊断和治疗。

关键词: 单基因脑小血管病; 神经系统症状; 神经系统外症状; 神经影像

Abstract: Cerebral small vessel disease (CSVD) is a group of neurological diseases with complex etiologies, mainly manifesting as ischemic or hemorrhagic stroke, cognitive impairment, emotional and psychiatric abnormalities, and gait disorders. Neuroimaging features include recent subcortical infarcts, enlarged perivascular spaces, cerebral microbleeds, intracranial hemorrhage, brain atrophy, lacunes of presumed vascular origin, and white matter lesions. Monogenic CSVD represents a rare subtype, accounting for 1% to 5% of all cases, with dozens of pathogenic genes reported to date. In addition to the common clinical and imaging manifestations of CSVD, monogenic CSVD often has specific symptoms, particularly extra-neurological symptoms, which have a strong indicative role in diagnosis. Given the time-consuming and challenging situation of genetic testing for CSVD-related genes, a comprehensive understanding of the neurological and extra-neurological symptoms of monogenic CSVD can facilitate early diagnosis and treatment. This article aims to summarize the neurological symptoms, extra-neurological symptoms, neuroimaging features, and their value for clinical diagnosis in monogenic CSVD.

Key words: Monogenic cerebral small vessel disease; Neurological symptom; Extra-neurological symptom; Neuroimaging

中图分类号:

蒋俊杰, 王梦文, 万艳, 胡波. 单基因脑小血管病的神经系统及神经系统外症状：对诊断的提示[J]. 中国卒中杂志, 2025, 20(6): 781-789.

JIANG Junjie, WANG Mengwen, WAN Yan, HU Bo. Neurological and Extra-Neurological Symptoms in Monogenic Cerebral Small Vessel Disease: Diagnostic Implications[J]. Chinese Journal of Stroke, 2025, 20(6): 781-789.

参考文献

[1] TER TELGTE A，VAN LEIJSEN E M C，WIEGERTJESW K，et al. Cerebral small vessel disease：from a focal to a global perspective[J]. Nat Rev Neurol，2018，14（7）：387-398.
[2] MANCUSO M，ARNOLD M，BERSANO A，et al. Monogenic cerebral small-vessel diseases：diagnosis and therapy. Consensus recommendations of the European Academy of Neurology[J]. Eur J Neurol，2020，27（6）：909-927.
[3] RANNIKMÄE K，HENSHALL D E，THRIPPLETON S，et al. Beyond the brain：systematic review of extracerebral phenotypes associated with monogenic cerebral small vessel disease[J]. Stroke，2020，51（10）：3007-3017.
[4] CHO B P H，HARSHFIELD E L，AL-THANI M，et al. Association of vascular risk factors and genetic factors with penetrance of variants causing monogenic stroke[J]. JAMA Neurol，2022，79（12）：1303-1311.
[5] DUPRÉ N，DRIEU A，JOUTEL A. Pathophysiology of cerebral small vessel disease：a journey through recent discoveries[J/OL]. J Clin Invest，2024，134（10）：e172841[2025-02-20]. https://doi.org/10.1172/JCI172841.
[6] WHITTAKER E，THRIPPLETON S，CHONG L Y W，et al. Systematic review of cerebral phenotypes associated with monogenic cerebral small-vessel disease[J/OL]. J Am Heart Assoc，2022，11（12）：e025629[2025-02-20]. https://doi.org/10.1161/JAHA.121.025629.
[7] RUTTEN J W，VAN EIJSDEN B J，DUERING M，et al. The effect of NOTCH3 pathogenic variant position on CADASIL disease severity：NOTCH3 EGFR 1-6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFR 7-34 pathogenic variant[J]. Genet Med，2019，21（3）：676-682.
[8] UEMURA M，NOZAKI H，KATO T，et al. HTRA1-related cerebral small vessel disease：a review of the literature[J/OL]. Front Neurol，2020，11：545[2025-02-20]. https://doi.org/10.3389/fneur.2020.00545.
[9] JEANNE M，GOULD D B. Genotype-phenotype correlations in pathology caused by collagen type Ⅳ alpha 1 and 2 mutations[J/OL]. Matrix Biol，2017，57/58：29-44[2025-02-20]. https://doi.org/10.1016/j.matbio.2016.10.003.
[10] RICE G I，RODERO M P，CROW Y J. Human disease phenotypes associated with mutations in TREX1[J]. J Clin Immunol，2015，35（3）：235-243.
[11] BUDHDEO S，DE PAIVA A R B，WADE C，et al. A rare cause of monogenic cerebral small vessel disease and stroke：cathepsin A-related arteriopathy with strokes and leukoencephalopathy（CARASAL）[J]. J Neurol，2022，269（12）：6673-6677.
[12] ZHOU Q，YANG D，OMBRELLO A K，et al. Early-onset stroke and vasculopathy associated with mutations in ADA2[J]. N Engl J Med，2014，370（10）：911-920.
[13] PALAIODIMOU L，KOKOTIS P，ZOMPOLA C，et al. Fabry disease：current and novel therapeutic strategies. A narrative review[J]. Curr Neuropharmacol，2023，21（3）：440-456.
[14] VERSCHUERE S，NAVASSIOLAVA N，MARTIN L，et al. Reassessment of causality of ABCC6 missense variants associated with pseudoxanthoma elasticum based on Sherloc[J]. Genet Med，2021，23（1）：131-139.
[15] BANERJEE G，COLLINGE J，FOX N C，et al. Clinical considerations in early-onset cerebral amyloid angiopathy[J]. Brain，2023，146（10）：3991-4014.
[16] LIU A R，YING S C. Aicardi-Goutières syndrome：a monogenic type Ⅰ interferonopathy[J/OL]. Scand J Immunol，2023，98（4）：e13314[2025-02-20]. https://doi.org/10.1111/sji.13314.
[17] MIZUNO T，MIZUTA I，WATANABE-HOSOMI A，et al. Clinical and genetic aspects of CADASIL[J/OL]. Front Aging Neurosci，2020，12：91[2025-02-20]. https://doi.org/10.3389/fnagi.2020.00091.
[18] STAM A H，KOTHARI P H，SHAIKH A，et al. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations[J]. Brain，2016，139（11）：2909-2922.
[19] TAN R，TRAYLOR M，RUTTEN-JACOBS L，et al New insights into mechanisms of small vessel disease stroke from genetics[J]. Clin Sci（Lond），2017，131（7）：515-531.
[20] DUPRÉ N，GUENIOT F，DOMENGA-DENIER V，et al. Protein aggregates containing wild-type and mutant NOTCH3 are major drivers of arterial pathology in CADASIL[J/OL]. J Clin Invest，2024，134（8）：e175789[2025-02-20]. https://doi.org/10.1172/JCI175789.
[21] HARA K，SHIGA A，FUKUTAKE T，et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease[J]. N Engl J Med，2009，360（17）：1729-1739.
[22] RATELADE J，KLUG N R，LOMBARDI D，et al. Reducing hypermuscularization of the transitional segment between arterioles and capillaries protects against spontaneous intracerebral hemorrhage[J]. Circulation，2020，141（25）：2078-2094.
[23] ZAGAGLIA S，SELCH C，NISEVIC J R，et al. Neurologic phenotypes associated with COL4A1/2 mutations：expanding the spectrum of disease[J/OL]. Neurology，2018，91（22）：e2078-e2088[2025-02-20]. https://doi.org/10.1212/WNL.0000000000006567.
[24] ARENDS M，WANNER C，HUGHES D，et al. Characterization of classical and nonclassical Fabry disease：a multicenter study[J]. J Am Soc Nephrol，2017，28（5）：1631-1641.
[25] HADFIELD K D，ROCK C F，INKSON C A，et al. HTRA1 inhibits mineral deposition by osteoblasts：requirement for the protease and PDZ domains[J]. J Biol Chem，2008，283（9）：5928-5938.
[26] CHIMENTI C，HAMDANI N，BOONTJE N M，et al. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease[J]. Am J Pathol，2008，172（6）：1482-1490.
[27] MACDERMOT K D，HOLMES A，MINERS A H. Anderson-Fabry disease：clinical manifestations and impact of disease in a cohort of 98 hemizygous males[J]. J Med Genet，2001，38（11）：750-760.
[28] ULIVI L，COSOTTINI M，MIGALEDDU G，et al. Brain MRI in monogenic cerebral small vessel diseases：a practical handbook[J]. Curr Mol Med，2022，22（4）：300-311.
[29] WU C J，WANG M W，WANG X G，et al. The genetic and phenotypic spectra of adult genetic leukoencephalopathies in a cohort of 309 patients[J]. Brain，2023，146（6）：2364-2376.
[30] CHO B P H，HARSHFIELD E L，AL-THANI M，et al. Association of vascular risk factors and genetic factors with penetrance of variants causing monogenic stroke[J]. JAMA Neurol，2022，79（12）：1303-1311.
[31] MÖNKÄRE S，KUULUVAINEN L，KUN-RODRIGUES C，et al. Whole-exome sequencing of Finnish patients with vascular cognitive impairment[J]. Eur J Hum Genet，2021，29（4）：663-671.
[32] SHUKLA A，KAUR P，NARAYANAN D L，et al. Genetic disorders with central nervous system white matter abnormalities：an update[J]. Clin Genet，2021，99（1）：119-132.
[33] RICHARDS S，AZIZ N，BALE S，et al. Standards and guidelines for the interpretation of sequence variants：a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med，2015，17（5）：405-424.
[34] VERDURA E，HERVÉ D，SCHARRER E，et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease[J]. Brain，2015，138（Pt 8）：2347-2358.